



# CURIS LIFESCIENCES LIMITED

CIN: U24230GJ2016PLC086559

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceuticals", pursuant to a deed of partnership dated June 2, 2010. Thereafter "M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation dated March 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/Deputy Registrar of Companies/Registrar of Companies, Central Processing Centre.

Registered Office: PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat -382110, India.

Company Secretary and Compliance Officer: Mr. Nikhil Purohit

Website: <https://curisls.com> E-Mail: [cs@curisls.com](mailto:cs@curisls.com) Telephone No: +91 99045 22543

The Issue is being made in accordance with Chapter IX of the SEBI ICDR Regulations (IPO of Small and Medium Enterprises) and the equity shares are proposed to be listed on EMERGE Platform of NSE.

NOTICE TO THE INVESTORS: CORRIGENDUM TO THE RED HERRING PROSPECTUS DATE OCTOBER 30, 2025 ("RHP") FILED WITH REGISTRAR OF COMPANIES, AHMEDABAD ON OCTOBER 30, 2025 AND PRE-ISSUE AND PRICE BAND ADVERTISEMENT PUBLISHED ON OCTOBER 31, 2025 ("CORRIGENDUM")

**PROMOTERS OF OUR COMPANY: MR. DHARMESH DASHARATHBHAI PATEL, MR. SIDDHANT JAYANTIBHAI PAWASIA, MR. PIYUSH GORDHANBHAI ANTALA AND MR. JAIMIK MANSUKHLAL PATEL**

## THE ISSUE

INITIAL PUBLIC ISSUE OF 21,50,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF CURIS LIFESCIENCES LIMITED ("CURIS" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ [•] LAKHS ("THE ISSUE"), OF WHICH 1,08,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE AGGREGATING TO ₹ [•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 20,42,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE AGGREGATING TO ₹ [•] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.59 % AND 25.26 %, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH.

## FOR RISK TO INVESTORS, REFER TO SECTION TITLED "RISK FACTORS" BEGINNING ON PAGE 25 OF THE RHP

This Corrigendum is with reference to the Red Herring Prospectus dated October 30, 2025 ("RHP") filed with Registrar of Companies, Ahmedabad on October 30, 2025 and the Pre-Issue and Price Band Advertisement published on October 31, 2025 in All Editions of English National Daily Newspaper, Financial Express, All Edition of Hindi National Daily Newspaper, Jansatta, and Ahmedabad Edition of Gujarati Daily Newspaper, Financial Express (Gujarati Being Regional Language of Gujarat Where our Registered Office is located).

1.) In furtherance to the disclosure made in the table under the heading "The Issue" in the chapter titled "The Issue" appearing on page no. 57 of the Red Herring Prospectus dated October 30, 2025 filed with the ROC, the Stock Exchange and the SEBI, it is clarified as under:

PRESENT ISSUE OF EQUITY SHARES BY OUR COMPANY IN TERMS OF THIS DRAFT RED HERRING PROSPECTUS	
Particulars	Details
<b>Of which</b>	
Allocation to Qualified Institutional Buyers.	Not more than 10,18,000 Equity Shares of ₹10/- each at an Issue Price of ₹ [•]/- per Equity Share each aggregating to ₹ [•] Lakhs.
<b>Of Which</b>	
Anchor Investor Portion	6,10,000 Equity Shares of ₹10/- each for cash at a price of ₹ [•]/- (including a Share premium of ₹ [•]/- per Equity Share) per share aggregating to ₹ [•] Lakhs.
Net QIB Portion (assuming Anchor Investor Portion is fully subscribed)	4,08,000 Equity Shares of ₹10/- each for cash at a price of ₹ [•]/- (including a Share premium of ₹ [•]/- per Equity Share) per share aggregating to ₹ [•] Lakhs
<b>Of which</b>	
Available for allocation to Mutual Funds only (5% of the Net QIB Portion)	21,000 Equity Shares of ₹10/- each for cash at a price of ₹ [•]/- (including a Share premium of ₹ [•]/- per Equity Share) per share aggregating to ₹ [•] Lakhs.
Balance of QIB Portion for all QIBs including Mutual Funds	3,87,000 Equity Shares of ₹10/- each for cash at a price of ₹ [•]/- (including a Share premium of ₹ [•]/- per Equity Share) per share aggregating to ₹ [•] Lakhs.
Allocation to Non-Institutional Investors	Not Less than 3,08,000 Equity Shares of ₹10/- each at an Issue Price of ₹ [•]/- per Equity Share each aggregating to ₹ [•] Lakhs.

However, the same shall be referred to as follows:

**Allocation to Qualified Institutional Buyers** shall be read as Not more than 10,17,000 Equity Shares of ₹10/- each at an Issue Price of ₹ [•]/- per Equity Share each aggregating to ₹ [•] Lakhs.

**Anchor Investor Portion** shall be read as Upto 6,09,000 Equity Shares of ₹10/- each for cash at a price of ₹ [•]/- (including a Share premium of ₹ [•]/- per Equity Share) per share aggregating to ₹ [•] Lakhs.

**Net QIB Portion (assuming Anchor Investor Portion is fully subscribed)** shall be read as Upto 4,08,000 Equity Shares of ₹10/- each for cash at a price of ₹ [•]/- (including a Share premium of ₹ [•]/- per Equity Share) per share aggregating to ₹ [•] Lakhs.

**Available for allocation to Mutual Funds only (5% of the Net QIB Portion)** shall be read as Upto 21,000 Equity Shares of ₹10/- each for cash at a price of ₹ [•]/- (including a Share premium of ₹ [•]/- per Equity Share) per share aggregating to ₹ [•] Lakhs.

**Balance of QIB Portion for all QIBs including Mutual Funds** shall be read as Upto 3,87,000 Equity Shares of ₹10/- each for cash at a price of ₹ [•]/- (including a Share premium of ₹ [•]/- per Equity Share) per share aggregating to ₹ [•] Lakhs.

**Allocation to Non-Institutional Investors** shall be read as Not Less than 3,09,000 Equity Shares of ₹10/- each at an Issue Price of ₹ [•]/- per Equity Share each aggregating to ₹ [•] Lakhs.

In this regard, the above details wherever appearing at all the relevant places in the Red Herring Prospectus dated October 30, 2025 filed with Registrar of Companies, Ahmedabad on October 30, 2025 and the Pre-Issue and Price Band Advertisement published on October 31, 2025 shall stand replaced with Revised Issue details as above.

2. **Footnotes to the table under the heading "Issue Expenses" in the chapter titled "Objects of the issue" on page no. 91 of the Red Herring Prospectus stand replaced with following:**

1. *Selling commission payable to the SCSBs on the portion for Individual Applicants. Non-Institutional Applicants, which are directly procured by the SCSBs, would be as follows:*

Portion for Individual Applicants*	₹ 0.01% per valid application (plus applicable taxes)
Portion for Non-Institutional Applicants*	₹ 0.01% per valid application (plus applicable taxes)

\*Amount allotted is the product of the number of Equity Shares Allotted and the Issue Price. The selling commission payable to the SCSBs will be determined on the basis of the bidding terminal ID as captured in the Bid Book of NSE.

2. *No uploading/ processing fees shall be payable by our Company to the SCSBs on the applications directly procured by them. Processing fees payable to the SCSBs on the portion for Individual Applicants and Non-Institutional Applicants which are procured by the members of the Syndicate/ sub-Syndicate/ Registered Broker/ CRTAs/ CDPs and submitted to SCSB for blocking, would be as follows:*

Portion for Individual Applicants*	₹ 10 per valid Bid cum Application Form (plus applicable taxes)
Portion for Non-Institutional Applicants*	₹ 10 per valid Bid cum Application Form (plus applicable taxes)

Notwithstanding anything contained above the total processing fee payable and selling commission payable to the SCSB under this clause will not exceed ₹ 0.5 Lakhs (plus applicable taxes) and in case if the total processing fees exceeds ₹ 0.5 Lakhs (plus applicable taxes) then processing fees will be paid on pro-rata basis

3. *The processing fees for applications made by Individual Applicants using the UPI Mechanism would be as follows:*

Members of the RTAs/ CDPs (uploading charges)	₹ 10 per valid application (plus applicable taxes)
Sponsor Bank	up to 25,000 Valid UPI Applications ₹ Nil /- per valid application - above 25,000 UPI valid applications - ₹ 6.50 + GST per UPI <i>The Sponsor Bank shall be responsible for making payments to the third parties such as remitter bank, NPCI and such other parties as required in connection with the performance of its duties under the SEBI circulars, the Syndicate Agreement and other applicable laws.</i>

\*For each valid application by respective Sponsor Bank

Notwithstanding anything contained above in this clause the total Uploading charges/ Processing fees payable to Members of the Syndicate/ RTAs/ CDPs for applications made by RIBs (up to ₹200,000), Non-Institutional Applicants (for an amount more than ₹200,000 and up to ₹500,000) using the UPI Mechanism and in case if the total uploading charges/ processing fees exceeds ₹0.5 Lakhs (plus applicable taxes) then uploading charges/ processing fees using UPI Mechanism will be paid on pro-rata basis.

4. *Selling commission on the portion for Individual Applicants and Non-Institutional Applicants which are procured by members of the Syndicate (including their sub-Syndicate Members), Registered Brokers, CRTAs and CDPs or for using 3-in-1 type accounts- linked online trading, demat & bank account provided by some of the Registered Brokers which are Members of the Syndicate (including their Sub-Syndicate Members) would be as follows:*

Portion for Individual Applicants*	₹10 per valid application (plus applicable taxes)
Portion for Non-Institutional Applicants*	₹10 per valid application (plus applicable taxes)

\*Amount Allotted is the product of the number of Equity Shares Allotted and the Issue Price

Uploading charges payable to Members of the Syndicate (including their sub-Syndicate Members), CRTAs and CDPs on the applications made by RIBs using 3-in-1 accounts and Non-Institutional Applicants which are procured by them and submitted to SCSB for blocking or using 3-in-1 accounts, would be as follows: 10 plus applicable taxes, per valid application bid by the Syndicate (including their sub-Syndicate Members), CRTAs and CDPs.

5. *Bidding charges payable to the Registered Brokers, CRTAs/ CDPs on the portion for RIBs and Non-Institutional Applicants which are directly procured by the Registered Brokers or CRTAs or CDPs and submitted to SCSB for processing, would be as follows:*

Portion for Individual Applicants*	₹ 10 per valid application (plus applicable taxes)
Portion for Non-Institutional Applicants*	₹ 10 per valid application (plus applicable taxes)

\*Based on valid applications

Notwithstanding anything contained above the total uploading/ bidding charges to the Registered Brokers payable/selling commission payable to the

SCSB under this clause will not exceed ₹0.5 Lakhs (plus applicable taxes) and in case if the total uploading/ bidding charges exceeds ₹0.5 Lakhs (plus applicable taxes) then uploading charges will be paid on pro-rata basis.


6. *The Selling Commission payable to the Syndicate/ Sub-Syndicate Members will be mutually decided between the parties to the agreement.*

For clarification, if a Syndicate ASBA application on the application form number/ series of a Syndicate/ Sub-Syndicate Member, is bid by an SCSB, the Selling Commission will be payable to the SCSB and not the Syndicate/ Sub-Syndicate Member. Bidding Charges payable to members of the Syndicate (including their sub-Syndicate Members), CRTAs and CDPs on the portion for RIBs and Non-Institutional Applicants which are procured by them and submitted to SCSB for blocking, would be as follows: ₹10 (plus applicable taxes), per valid application bid by the Syndicate (including their sub-Syndicate Members), CRTAs and CDPs.

The selling commission and bidding charges payable to Registered Brokers the CRTAs and CDPs will be determined on the basis of the bidding terminal ID as captured in the Bid Book of NSE Limited.

All such commissions and processing fees set out above shall be paid as per the timelines in terms of the Syndicate Agreement and Escrow and Sponsor Bank Agreement. Further, the processing fees for applications made by UPI Applicants using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI Circular No: SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI Circular No: SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021.

The processing fees for applications made by Individual Bidders using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI Circular No: SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 as amended pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 02, 2021 read with SEBI Circular No: SEBI/HO/CFD/DIL2/CIR/P/2022/51 April 20, 2022.




<b>ASBA*</b>	Simple, Safe, Smart way of Application – Make use of it!!!	*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below.	Mandatory in Public Issues from January 01, 2016. No cheque will be accepted
	UPI-Now available in ASBA for Individual Investors and Non Individual Investor applying for amount up to Rs. 5,00,000/- applying through Registered Brokers, DP's & RTAS. UPI Bidder also have option to submit the Application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the Bank Account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhar and are in compliance with CBDT notification dated February 13, 2020, issued by CBDT and the subsequent press release, including press release dated June 25, 2021 and September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press release in this regard.		

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by (1) Individual Investors Portion. (ii) Non-Institutional Investors with an application size of up to 5,00,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the chapter titled "Issue Procedure" beginning on page 326 of the Red Herring Prospectus. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of Stock Exchanges and can be obtained from the list of banks that is displayed on the website of SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid-35> and <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid-43>, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: [www.sebi.gov.in](http://www.sebi.gov.in). UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. Axis Bank Limited has been appointed as Sponsor Banks and for the Issue, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For Issue related queries, please contact the BRLM on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll-free number: 18001201740 and mail id: [ipo.upi@npci.org.in](mailto:ipo.upi@npci.org.in).

The Red Herring Prospectus shall be read in conjunction with this Corrigendum. The information in this Corrigendum supersedes the information in the RHP/ Pre-Issue and Price Band Advertisement to the extent inconsistent with the information in the RHP/ Pre-Issue and Price Band Advertisement. The RHP/ Pre-Issue and Price Band Advertisement accordingly stands amended to the extent stated hereinabove. Relevant changes shall be reflected in the Prospectus as and when filled with the RoC, SEBI AND NSE. Unless otherwise specified, all capitalized terms used herein shall have the same meaning ascribed to such terms in the RHP.

**DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"):** Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018. The Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Issue Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 302 of the Red Herring Prospectus.

**DISCLAIMER CLAUSE OF NSE ("NSE EMERGE") (THE DESIGNATED STOCK EXCHANGE):** It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Issue Documents has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Issue Documents. The investors are advised to refer to the issue document for the full text of the 'Disclaimer Clause of NSE.'

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <b>FINAAX CAPITAL ADVISORS PRIVATE LIMITED</b> Address: B-401, The First, B/s Keshavbaug Party Plot, II M, Ahmedabad-380015, Gujarat, India Telephone Number: +91 94295 50695/ 95375 94321 Email Id: <a href="mailto:info@finaaxcapital.com">info@finaaxcapital.com</a> Investors Grievance Id: <a href="mailto:investors@finaaxcapital.com">investors@finaaxcapital.com</a> Website: <a href="http://www.finaaxcapital.com">www.finaaxcapital.com</a> Contact Person: Mr. Ikshit Shah/Mr. Yash Doshi CIN: U64990GJ2023PTC147118 SEBI Registration Number: INM000013244	 <b>MUFG INTIME INDIA PRIVATE LIMITED</b> (Formerly Link Intime India Private Limited) Address: C- 101, 247 Park, L B S Marg, Vikhroli West, Mumbai-400083, Maharashtra; Tel No.: +91 810 811 4949 Email Id: <a href="mailto:curislifesciences.smeipo@in.mpmms.mufg.com">curislifesciences.smeipo@in.mpmms.mufg.com</a> Investors Grievance Email: <a href="mailto:curislifesciences.smeipo@in.mpmms.mufg.com">curislifesciences.smeipo@in.mpmms.mufg.com</a> Website: <a href="http://www.in.mpmms.mufg.com">www.in.mpmms.mufg.com</a> Contact Person: Ms. Shanti Gopalkrishnan; SEBI Registration No.: INR000004058; CIN: U67190MH1999PTC118368.	 <b>Mr. Nikhil Purohit</b> CURIS LIFESCIENCES LIMITED Address: PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat, India, 382110. Telephone No.: +91 99045 22543 Website: <a href="https://curisls.com">https://curisls.com</a> E-Mail: <a href="mailto:cs@curisls.com">cs@curisls.com</a> Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-issue or post-issue related grievances including non-rcipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non-rcipt of funds by electronic mode etc., For all Issue related queries and for redressal of complaints Investors may also write to the BRLM.

On behalf of Board of Directors

FOR, CURIS LIFESCIENCES LIMITED

Sd/-

Nikhil Purohit

Company Secretary & Compliance Officer

Place: Sanand, Gujarat

Date: November 6, 2025

**Disclaimer:** Curis Lifesciences Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public Issue of its Equity Shares the Red Herring Prospectus dated October 30, 2025 has been filed with the Registrar of Companies, Ahmedabad and thereafter with SEBI and the Stock Exchanges. The RHP is available on the website of the SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), website of NSE Emerge at [https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme\\_offer](https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme_offer) and is available on the websites of the BRLM at [www.finaaxcapital.com](http://www.finaaxcapital.com). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Red Herring Prospectus including the chapter titled "Risk Factors" beginning on page 25 of the Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.